EUVIMEDEUVIMED entdecken
Crossref

Etripamil Nasal Spray (Cardamyst) for Paroxysmal Supraventricular Tachycardia

The Medical Letter on Drugs and Therapeutics · 13.04.2026 · 68 (1752) · 59-61

DOI: 10.58347/tml.2026.1752b ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 13.04.2026.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved Cardamyst (Milestone), a nasal spray formulation of the nondihydropyridine calcium channel blocker etripamil, for conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Cardamyst is the first product containing etripamil to be approved in the US. It is being marketed as the only FDA-approved, self-administered, rapid-acting treatment option for acute episodes of PSVT.

Schlagwörter

Stichwörter der Autor:innen

Cardamystadverse effectsdiltiazemdosageefficacyesmololetripamillactationmetoprololpregnancypropranololsafetytachycardiaverapamil

Zitieren

APA

(2026). Etripamil Nasal Spray (Cardamyst) for Paroxysmal Supraventricular Tachycardia. The Medical Letter on Drugs and Therapeutics, 68(1752), 59-61. https://doi.org/10.58347/tml.2026.1752b

Vancouver

Etripamil Nasal Spray (Cardamyst) for Paroxysmal Supraventricular Tachycardia. The Medical Letter on Drugs and Therapeutics. 2026;68(1752):59-61. doi:10.58347/tml.2026.1752b

BibTeX
@article{euvimed2026,
  title = {Etripamil Nasal Spray (Cardamyst) for Paroxysmal Supraventricular Tachycardia},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1752},
  pages = {59--61},
  doi = {10.58347/tml.2026.1752b}
}
Kostenlos starten →